Ahmedabad, India, August 13, 2025 – Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed an agreement today to acquire two products of USFDA-approved Abbreviated New Drug Applications (“ANDAs”) from Teva Pharmaceuticals USA, Inc.
The addressable opportunity of the acquired ANDAs in the USA is ~USD 38 Mn (MAT December 2024)* as per IQVIA and ~USD 120 Mn (MAT June 2025)# as per the speciality data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by SPL. This is in line with the objects of the IPO stated in the Red Herring Prospectus.
About Senores Pharmaceuticals Limited:
Senores Pharmaceuticals Limited (together with its subsidiaries “Senores”) is a global, research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The companies’ current portfolio includes 70 ANDA and 27 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 308 product registrations and 719 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”).
Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).
Leave a Reply